0000000000077745

AUTHOR

Ilaria Morreale

showing 12 related works from this author

A questionable diagnosis in a woman with drowsiness

2019

A 60-year-old caucasian woman was admitted to our Division of Internal Medicine for a 10-day history of drowsiness, irritability, dysphasia, weakness and difficulties in the maintenance of an upright position with numerous falls, with a traumatic lumbar spine injury and on the left shoulder. Then, while general clinical conditions were getting worse with drowsiness and hyposthenia of the right side of the body, after neurological evaluation, she was recovered in hospital. Pathological history includes a 20-year epilepsy and depression with emotional lability, behavior’s disorders and attempted suicide. For such reason, she was followed in a mental health institute, treated with phenobarbita…

Depressionbusiness.industryMiddle Agedmedicine.diseaseDiagnosis DifferentialBenzodiazepinesPhenobarbitalEmergency MedicineInternal MedicineHumansMedicineFemaleMedical emergencyDrug OverdoseStuporPhenobarbital intoxication clinical case drug induced liver injurybusinessBiomarkers
researchProduct

Protocol of BRONJ prevention: successful use of antiseptics during oral surgical procedures

2012

Aim: The overall prevention and treatment of Bisphosphonates related osteonecrosis of the jaws (BRONJ) have been the goals of our project structured (labelled PROMaB) within the hospital AOUP “P. Giaccone” (Italy) in order to make better quality life of patients in therapy with amminobisphosphonates (NBP). Material and Methods: Among all procedures, in case of preprogrammed oral surgical procedure, oral antimicrobial rinses (i.e. chlorexidine 0,2% mouthwash and 0,5% gel, three times/day) plus oral systemic antibiotic therapy –e.g. amoxicilin/clavulanate- have been used to reduce the risk of BRONJ in secondary prevention (1 day before and 6 days after). Three hundred and twenty-one patients …

BRONJ prevention antiseptics oral surgerySettore MED/28 - Malattie Odontostomatologiche
researchProduct

Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

2012

PURPOSE: Fluoroquinolones are popular and widely used in primary care and hospital settings. Premarketing studies showed a favourable side-effect profile. However, significant morbidity and the need for liver transplantation for acute liver failure have been reported. We reviewed the available data on liver damage linked to fluoroquinolones. METHODS: A systematic search of case reports on the MEDLINE database encompassing the years 2000-2011 was carried out. Additional references were found by a manual search of the retrieved paper. We also describe three new cases of hepatotoxicity attributable to fluoroquinolones seen at our Unit. RESULTS: Thirty-five cases were retrieved from MEDLINE (51…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentTreatment outcomePrimary careLiver transplantationfluoroquinoloneSeverity of Illness IndexSeverity of illnessMedicineHumansPharmacology (medical)Liver damageIntensive care medicinePharmacologyHepatitisLiver injurySettore MED/12 - Gastroenterologiabusiness.industryLiver failureGeneral MedicineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsTreatment OutcomeItalyliver damageSettore BIO/14 - FarmacologiaFemaleDILIChemical and Drug Induced Liver InjurybusinessFluoroquinolones
researchProduct

Findings of osteonecrosis of the jaw under combined bisphosphonate and antiangiogenic therapies: an emergent problem?

2011

antiangiogenic agentsSettore MED/09 - Medicina InternaOsteonecrosis of the jawSettore MED/28 - Malattie OdontostomatologicheSettore BIO/14 - Farmacologiabisphosponate
researchProduct

Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literatu…

2021

Ruxolitinib side effects include the most frequent hematological toxicity along with a more recently evidenced immunosuppressive activity, interfering both with the innate and adaptive immunity, and several cases of reactivation of latent infections by opportunistic agents in patients in treatment with ruxolitinib have been published in the last years. Several pathophysiological mechanisms may explain an association between ruxolitinib and opportunistic infections. From what we know, the only case of an isolated lymph node TBC reactivation in a ruxolitinib-treated myelofibrosis (MF) patient was reported by Patil et al. in 2016 [Int J Med Sci Public Health. 2017;6(3):1]. Other 10 cases descr…

Oncologymedicine.medical_specialtyRuxolitinibConstitutional symptomsSettore MED/15 - Malattie Del SangueHematological toxicityInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientMyelofibrosisProspective cohort studyLymph nodePharmacologybusiness.industryInfection Myelofibrosis Reactivation Tuberculosis Ruxolitinib TBCGeneral Medicinemedicine.diseaseInfectious Diseasesmedicine.anatomical_structureOncologySputummedicine.symptombusinessmedicine.drug
researchProduct

Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Ca…

2018

The study presents a report of 58 metastatic cancer patients who developed osteonecrosis of the jaws after being treated with zoledronic acid and taxanes, plus corticosteroids. A retrospective analysis of data registered in the archives of two Italian osteonecrosis of the jaws treatment centers, who are based at the University of Messina and at the University of Palermo, was performed in order to study, in these patients, demographic data and characteristics such as frequency of cancer location, lines of therapy, frequency of cancer drugs, presence/absence of oral trigger, number, location, and stage of jaw osteonecrosis. It was found that the majority of patients developed advanced stages …

DrugGenetics and Molecular Biology (all)Malemedicine.medical_specialtyExacerbationArticle SubjectImmunology and Microbiology (all)media_common.quotation_subjectlcsh:MedicineClinical manifestationBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsmedicineHumansDrug InteractionsStage (cooking)media_commonRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)General Immunology and MicrobiologyBone Density Conservation AgentsDiphosphonatesbusiness.industrylcsh:ROsteonecrosisSoft tissueCancer030206 dentistryGeneral Medicinemedicine.diseaseZoledronic acidBiochemistry Genetics and Molecular Biology (all) Immunology and Microbiology (all)Italy030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleTaxoidsbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugResearch ArticleBioMed Research International
researchProduct

Farmacovigilanza in oncologia: la nostra esperienza nel "Centro di consulenza ed informazione sugli effetti tossici da farmaci antitumorali e sulle A…

2009

La segnalazione delle reazioni avverse da farmaci (ADR) in ambito post-marketing è fondamentale per la tempestiva identificazione di nuove, in particolare gravi, tossicità, che, non emergono facilmente nei trial pre-registrativi.per vari limiti. La farmacovigilanza (FV) è necessaria per una identificazione più completa della sicurezza e dell’impatto sulla qualità di vita di un nuovo medicamento nella pratica clinica reale, dove i pazienti, per differenti ragioni (patologie multiple, corredo genetico, usi off-label, etc.) sono a maggior rischio di ADR e di interazioni tra farmaci. In passato i farmaci antineoplastici non sono stati oggetto di attenzione prioritaria nei programmi nazionali o …

Settore BIO/14 - FarmacologiaFarmacovigilanza Farmaci antitumorali
researchProduct

The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients

2015

Background Proton pump inhibitors (PPIs) are among the most misused drugs both at the community and hospital level. Recently, possible risks have been underscored, suggesting the importance of limiting PPI use to proven indications. Objective To survey the appropriateness of PPI use in a University hospital in Italy. Setting Azienda Ospedaliera Universitaria Policlinico ‘P. Giaccone’, in Palermo, Italy. Method A one day-observational study, reviewing patients’ medical records to identify treatments with PPIs and the indications for their use. After discharge, a subgroup of the cohort was followed up to assess the continuation of therapy at home. Appropriateness was evaluated according to th…

AdultMaleDrug UtilizationDrugmedicine.medical_specialtyIcu patientsmedia_common.quotation_subjectPharmaceutical ScienceInappropriate PrescribingPharmacyPharmacyProton pump inhibitorToxicologyHospitals UniversityHospitalmedicineDrug utilizationHumansPharmacology (medical)Stomach UlcerMedical prescriptionIntensive care medicineAgedmedia_commonPharmacologybusiness.industryMedical recordStress ulcerProton Pump InhibitorsMiddle Agedmedicine.diseasePatient DischargeHospitalizationTherapeutic appropriateneItalyPractice Guidelines as TopicCohortSettore BIO/14 - FarmacologiaFemaleGuideline Adherencebusiness
researchProduct

Use of herbal products among cancer and transplanted patients in the town of Palermo,Sicily.

2010

Herbal productscancer patientstransplanted patientsSettore BIO/14 - Farmacologia
researchProduct

Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib.

2018

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected …

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentlenvatinibMRONJ03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineAnimalsHumansThyroid cancerbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryPhenylurea CompoundsOsteonecrosis030206 dentistryMiddle Agedmedicine.diseaseosteonecrosis of the jawOtorhinolaryngologyDental extractionchemistryRANKL030220 oncology & carcinogenesisConcomitantbiology.proteinQuinolinesSurgeryBisphosphonate-Associated Osteonecrosis of the Jawdental extractionOral SurgerybusinessLenvatinibOsteonecrosis of the jawTyrosine kinaseAdverse drug reactionInternational journal of oral and maxillofacial surgery
researchProduct

La segnalazione delle reazioni avverse da farmaci in oncologia: considerazioni di base e analisi dell'esperienza organizzativa e scientifica nella Re…

2011

considerazioni di basereazioni avverse da farmaci in oncologiaSettore BIO/14 - FarmacologiaRegione Sicilia.analisi dell'esperienza organizzativa e scientifica
researchProduct

Rivaroxaban-induced hepatotoxicity

2017

Aim/Objective/Background Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we report two new cases of rivaroxaban-induced hepatitis. Methods A systematic search of case reports on the MEDLINE database encompassing the years 2008–2016 was carried out.Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse events occurred in patients treated w…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_mechanism_of_actionFactor Xa InhibitorMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansAgedAged 80 and overSecondary preventionRivaroxabanHepatologybusiness.industryGastroenterologydrug-induced liver injury hepatotoxicity pharmacovigilancerivaroxabanOral anticoagulantFemale030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFactor Xa Inhibitorsmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct